These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24370059)

  • 21. Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics.
    Tasian SK; Hunger SP
    Br J Haematol; 2017 Mar; 176(6):867-882. PubMed ID: 27984637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis.
    Foroni L; Harrison CJ; Hoffbrand AV; Potter MN
    Br J Haematol; 1999 Apr; 105(1):7-24. PubMed ID: 10366253
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacogenomics of pediatric acute lymphoblastic leukemia.
    Meeker ND; Yang JJ; Schiffman JD
    Expert Opin Pharmacother; 2010 Jul; 11(10):1621-32. PubMed ID: 20429672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
    Ribera JM; Oriol A; Morgades M; Montesinos P; Sarrà J; González-Campos J; Brunet S; Tormo M; Fernández-Abellán P; Guàrdia R; Bernal MT; Esteve J; Barba P; Moreno MJ; Bermúdez A; Cladera A; Escoda L; García-Boyero R; Del Potro E; Bergua J; Amigo ML; Grande C; Rabuñal MJ; Hernández-Rivas JM; Feliu E
    J Clin Oncol; 2014 May; 32(15):1595-604. PubMed ID: 24752047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Minimal residual disease in childhood acute lymphoblastic leukemia: diagnosis of the 21 century].
    Szczepański T; Sońta-Jakimczyk D; Van Dongen JJ
    Przegl Lek; 2003; 60 Suppl 5():1-4. PubMed ID: 14574999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapy for childhood acute lymphoblastic leukemia.
    Cassano WF; Eskenazi AE; Frantz CN
    Curr Opin Oncol; 1993 Jan; 5(1):42-52. PubMed ID: 8427893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?
    Balduzzi A; Di Maio L; Silvestri D; Songia S; Bonanomi S; Rovelli A; Conter V; Biondi A; Cazzaniga G; Valsecchi MG
    Br J Haematol; 2014 Feb; 164(3):396-408. PubMed ID: 24422724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
    Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
    N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
    Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P
    Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Acute lymphoblastic leukemia (ALL)].
    Imai K; Akiyama H
    Gan To Kagaku Ryoho; 2007 Dec; 34(13):2180-4. PubMed ID: 18079617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimal residual disease in childhood acute lymphoblastic leukemia: current status and challenges.
    Izraeli S; Waldman D
    Acta Haematol; 2004; 112(1-2):34-9. PubMed ID: 15179003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Monitoring minimal residual disease in pediatric patients with acute lymphoblastic leukemia].
    Zuna J; Hrusák O; Kalinová M; Muzíková K; Zörnerová T; Starý J; Trka J
    Vnitr Lek; 2000 Aug; 46(8):465-9. PubMed ID: 11048511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minimal residual disease directed therapy for childhood acute myeloid leukaemia: the time is now.
    Goulden N; Virgo P; Grimwade D
    Br J Haematol; 2006 Aug; 134(3):273-82. PubMed ID: 16848770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical significance of glucocorticoid induction test in Chinese childhood acute lymphoblastic leukemia].
    Fan JJ; Chai YH; Hu SY; He HL; Zhao WL; Wang Y; Li J; Lu J; Xiao PF; Sun YN; Wang W; Cao L
    Zhonghua Er Ke Za Zhi; 2013 Jul; 51(7):523-6. PubMed ID: 24267134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenomics of childhood acute lymphoblastic leukemia.
    Brenner TL; Pui CH; Evan WE
    Curr Opin Mol Ther; 2001 Dec; 3(6):567-78. PubMed ID: 11804271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence.
    Bleckmann K; Schrappe M
    Br J Haematol; 2016 Mar; 172(6):855-69. PubMed ID: 26773444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
    Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
    Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia.
    Evans WE; Relling MV; Rodman JH; Crom WR; Boyett JM; Pui CH
    N Engl J Med; 1998 Feb; 338(8):499-505. PubMed ID: 9468466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of minimal residual disease in leukemia using polymerase chain reaction and restriction analysis.
    Wu N; Lu S; Zhu P; Liu L; Peng Y
    Chin Med J (Engl); 1997 Jan; 110(1):73-7. PubMed ID: 9594329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
    Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
    J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.